OBJECTIVE: To investigate the association between CD133 expression and prognosis and clinicopathological features of ovarian cancer. METHODS: The electronic and manual searches were performed through the database of PubMed Chinese Wanfang databases (up to September 15, 2014) was performed using the following keywords ovarian cancer, CD133, AC133, prominin-1. Meta-analysis was performed by using Review Manager 5.2 and the outcomes included the overall survival and various clinicopathological features. RESULTS: A total of 1051 ovarian cancer patients from 8 studies were included. Meta-analysis showed that overexpression of CD133 was highly correlated with reduced 2-year overall survival (OR = 1.67, 95% CI: 1.06-2.63, P = 0.03, fixed-effect). With respect to clinicopathological features, CD133 level was positively correlated with tumor stage (OR = 0.26, 95% CI: 0.12-0.58, P = 0.001 random-effect). But not correlated with patients' age (OR = 1.12, 95% CI: 0.68-1.86, P = 0.65 fixed-effect), tumor grade (OR = 1.20, 95% CI: 0.06-1.62, P = 0.17 random-effect), histological type (OR = 1.10, 95% CI: 0.82-1.47, P = 0.54 fixed-effect) and response to treatment (OR = 0.84, 95% CI: 0.61-1.16, P = 0.29 fixed-effect). CONCLUSION: On the basis of current retrospective evidence, the present meta-analysis indicated that high level of CD133 expression trends to correlate with a worse prognosis in patients with ovarian cancer.
OBJECTIVE: To investigate the association between CD133 expression and prognosis and clinicopathological features of ovarian cancer. METHODS: The electronic and manual searches were performed through the database of PubMed Chinese Wanfang databases (up to September 15, 2014) was performed using the following keywords ovarian cancer, CD133, AC133, prominin-1. Meta-analysis was performed by using Review Manager 5.2 and the outcomes included the overall survival and various clinicopathological features. RESULTS: A total of 1051 ovarian cancerpatients from 8 studies were included. Meta-analysis showed that overexpression of CD133 was highly correlated with reduced 2-year overall survival (OR = 1.67, 95% CI: 1.06-2.63, P = 0.03, fixed-effect). With respect to clinicopathological features, CD133 level was positively correlated with tumor stage (OR = 0.26, 95% CI: 0.12-0.58, P = 0.001 random-effect). But not correlated with patients' age (OR = 1.12, 95% CI: 0.68-1.86, P = 0.65 fixed-effect), tumor grade (OR = 1.20, 95% CI: 0.06-1.62, P = 0.17 random-effect), histological type (OR = 1.10, 95% CI: 0.82-1.47, P = 0.54 fixed-effect) and response to treatment (OR = 0.84, 95% CI: 0.61-1.16, P = 0.29 fixed-effect). CONCLUSION: On the basis of current retrospective evidence, the present meta-analysis indicated that high level of CD133 expression trends to correlate with a worse prognosis in patients with ovarian cancer.
Entities:
Keywords:
CD133; Ovarian cancer; cancer stem cells; prognosis
Authors: Michael L O'Connor; Dongxi Xiang; Sarah Shigdar; Joanna Macdonald; Yong Li; Tao Wang; Chunwen Pu; Zhidong Wang; Liang Qiao; Wei Duan Journal: Cancer Lett Date: 2013-12-11 Impact factor: 8.679
Authors: Virginia Tirino; Vincenzo Desiderio; Francesca Paino; Alfredo De Rosa; Federica Papaccio; Marcella La Noce; Luigi Laino; Francesco De Francesco; Gianpaolo Papaccio Journal: FASEB J Date: 2012-09-28 Impact factor: 5.191
Authors: Jing Zhang; Xiaoqing Guo; Doo Young Chang; Daniel G Rosen; Imelda Mercado-Uribe; Jinsong Liu Journal: Mod Pathol Date: 2011-11-11 Impact factor: 7.842
Authors: Lisa M Landrum; James Java; Cara A Mathews; Grainger S Lanneau; Larry J Copeland; Deborah K Armstrong; Joan L Walker Journal: Gynecol Oncol Date: 2013-04-08 Impact factor: 5.482
Authors: Shuyan Liu; Chengfei Liu; Xiaoyun Min; Yuanyuan Ji; Na Wang; Dan Liu; Jiangyi Cai; Ke Li Journal: PLoS One Date: 2013-11-25 Impact factor: 3.240
Authors: Shreya Raghavan; Pooja Mehta; Maria R Ward; Michael E Bregenzer; Elyse M A Fleck; Lijun Tan; Karen McLean; Ronald J Buckanovich; Geeta Mehta Journal: Clin Cancer Res Date: 2017-08-16 Impact factor: 12.531
Authors: Brandt C Huddle; Edward Grimley; Cameron D Buchman; Mikhail Chtcherbinine; Bikash Debnath; Pooja Mehta; Kun Yang; Cynthia A Morgan; Siwei Li; Jeremy Felton; Duxin Sun; Geeta Mehta; Nouri Neamati; Ronald J Buckanovich; Thomas D Hurley; Scott D Larsen Journal: J Med Chem Date: 2018-09-28 Impact factor: 7.446
Authors: Eric N Horst; Michael E Bregenzer; Pooja Mehta; Catherine S Snyder; Taylor Repetto; Yang Yang-Hartwich; Geeta Mehta Journal: Acta Biomater Date: 2021-04-30 Impact factor: 10.633